1MacKay J.H. et al.Losartan and low-dose hydrochlorothiazide in patients with essential hypertension[].Archives of Internal Medicine.1996
2O` Hollaren MT.Porter M: Angiotension converting enzyme inhibitors and the allergist[].Annals of Allergy Asthma Immunology.1990
3Woo KS,Nicholls MG.High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese[].British Journal of Clinical Pharmacology.1995
4Tikkanen I,Omvik P,Jensen H A.Comparison of the angiotensin Ⅱ antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension[].Journal of Hypertension.1995
5Edwards RM,Trizna W,Stack EJ.Interaction of nonpeptide angiotension Ⅱ receptopr antagonists with the urate ransporter in rat renal brush-border membranes[].Journal of Pharmacology and Experimental Therapeutics.1996
6Dahlof B,Keller SE,Makrisl L,et al.Efficacy and tolerability of losartan potassium and atenolol in patient with mild to moderate essential hypertension[].American Journal of Hypertension.1995
6Lopez AD,Mathers CD,Ezzati M,et al.Global and regionalburden of disease and risk factors,2001 systematic analysis ofpopulation health data[J].Lancet,2006,367(9524):1747-1757.
7Daneshtalab N, Lewanczuk R Z, Jamali F. High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method[J]. J Chromatogr B, 2002, 766 : 345-349.
8Vignaduzzo S E, CasteUano P M, Kaufman T S. Development andvalidation of an HPLC method for the simultaneous determination of amlodipine,hydrochlorothiazide and valsartan in tablets of their novel triple combination and binary pharmaceutical associations[J]. J Liquid Chromatogr Related Technol, 2011, 34: 2383-2395.
9美国药典委员会.USP35-NF30[M].2012:5555-5556.
10Fortmann SP, Flora JA, Winkeby MA, et al. Community interven- tion trials:reflections on the Stanford Five-City Project Experience [ J ]. Am J Epidemio1,2010,142 ( 11 ) :576-586.
